Biogen Analysts Slash Their Forecasts After Q3 Results
Biogen Analysts Slash Their Forecasts After Q3 Results
For 2024 compared to 2023, Biogen expects operating income to grow at a high-teen percentage with mid-single digit percentage point operating margin improvementBiogen Inc (NASDAQ:BIIB) reported upbeat earnings for the third quarter on Wednesday.
渤健公司（納斯達克：BIIB）週三報告稱，第三季度盈利表現樂觀。
The company pisted third-quarter adjusted EPS of $4.08, down 6%, beating the consensus of $3.79. The company reported sales of $2.47 billion, down 3% year over on constant currency and reported basis, beating the consensus of $2.43 billion.
公司發佈了第三季度調整後的每股收益爲4.08美元，下降6%，超過了3.79美元的共識。公司報告的銷售額爲24.7億美元，按恒定貨幣和報告基礎計算，同比下降3%，超過了24.3億美元的共識。
Biogen raised its 2024 adjusted EPS guidance to $16.10-$16.60 versus prior guidance of $15.75-$16.25 and consensus of $16.19. Biogen continues to expect 2024 revenue to decline by a low-single-digit percentage, with core pharmaceutical revenue to be relatively flat compared to 2023, as further declines in multiple sclerosis product revenues are expected to be offset by increases in revenue from new product launches.
渤健公司將其2024年調整後的每股收益指引上調至16.10-16.60美元，而之前的指引爲15.75-16.25美元，共識爲16.19美元。渤健公司預計2024年營業收入將以低個位數百分比下降，核心藥品營收相對於2023年將保持相對穩定，多發性硬化產品營收的進一步下降將被新產品發佈帶來的營收增長所抵消。
For 2024 compared to 2023, Biogen expects operating income to grow at a high-teen percentage with mid-single digit percentage point operating margin improvement
2024年相比於2023年，渤健公司預計營業利潤將以高個位數百分比增長，營業利潤率將提高中個位數百分比。
Biogen shares fell 2.5% to trade at $176.55 on Thursday.
週四，渤健公司股價下跌2.5%，報收176.55美元。
These analysts made changes to their price targets on Biogen following earnings announcement.
這些分析師根據盈利公告對渤健公司的價格目標做出了調整。
- Morgan Stanley analyst Matthew Harrison downgraded Biogen from Overweight to Equal-Weight and lowered the price target from $285 to $204.
- TD Cowen analyst Phil Nadeau maintained the stock with a Buy and lowered the price target from $300 to $275.
- Needham analyst Ami Fadia reiterated Biogen with a Buy and maintained a $270 price target.
- HC Wainwright & Co. analyst Andrew Fein reiterated Biogen with a Buy and maintained a $300 price target.
- 摩根士丹利分析師馬修·哈里森將渤健公司的評級從超重調降至等權，將價格目標從285美元下調至204美元。
- TD Cowen分析師菲爾·納多維以買入的評級維持了該股，並將價格目標從300美元下調至275美元。
- Needham分析師Ami Fadia重申買入渤健公司，並保持270美元的目標價。
- HC Wainwright & Co.分析師Andrew Fein重申買入渤健公司，並保持300美元的目標價。
Considering buying BIIB stock? Here's what analysts think:
正在考慮購買BIIb股票嗎？這是分析師的看法：
Read More:
閱讀更多：
- Jim Cramer: This Financial Stock Is 'One Of The Most Consistent, Great Companies'
- 吉姆·克雷默: 這家金融股是'最穩定、最優秀的公司之一'
譯文內容由第三人軟體翻譯。
